All-in-one milling platforms: How to reduce your machinery footprint
The pharmaceutical industry is currently experiencing a surge in novel drug candidates. These new drug approvals are leading to a …
Post
-
-
Trump 2.0 could see a rise in biopharmaceutical M&A deals
Trump’s return to the White House will mean a shift in personnel at the US Federal Trade Commission (FTC), which …
-
From Cobenfy to Emraclidine: the muscarinic path to safer antipsychotics
On 26 September 2024, Cobenfy (KarXT) gained US Food and Drug Administration (FDA) approval as the first novel class of …
-
Lundbeck acquires all outstanding shares of Longboard Pharma
Lundbeck has completed the acquisition of all outstanding shares of Longboard Pharmaceuticals, to bolster its capabilities in the neuro-rare disease …
-
Novartis and Olema expand alliance with $250m to boost breast cancer trials
Olema Oncology has announced another clinical trial collaboration and supply agreement with Novartis for a Phase III trial in metastatic …
-
Navigating medicine pricing in Turkiye: the pharmaceutical Euro exchange rate
In recent years, Turkiye’s pharmaceutical industry has grappled with significant economic challenges, not least of which is the frequent upward …
-
J&J’s sBLAs seek FDA approval of TREMFYA for paediatric conditions
Johnson & Johnson (J&J) has sought approval for TREMFYA (guselkumab) for paediatric conditions with the submission of two supplemental biologics licence …
-
Novartis and PTC Therapeutics link to develop Huntington’s therapy
Novartis has entered a worldwide licensing and partnership agreement with PTC Therapeutics to develop PTC518, a potential oral therapy for …
-
Faron Pharma secures UK innovation passport for blood cancer immunotherapy
Faron Pharmaceuticals is advancing its cancer immunotherapy programme in the UK, with the region’s regulatory authorities approving the advancement of …
-
Fate Therapeutics makes Bob Valamehr president and CEO
Fate Therapeutics has announced the retirement of president and CEO Scott Wolchko on 31 December 2024, with current research and development …
-
CHMP recommends oral peanut allergy immunotherapy treatment for toddlers
The European Medicines Agency’s (EMAs) Committee for Medicinal Products for Human Use (CHMP) has recommended extending the use of Stallergenes …
-
Meet the company on a mission to reengineer drug development
We’ve all seen the statistics. Drug development has a scarily high attrition rate, with approximately 90% of candidates falling short. …
-
CBC acquires UCB’s neurology and allergy business in China
CBC Group, in partnership with the Mubadala Investment Company, has completed the strategic acquisition of Union Chimique Belge's (UCB) mature …
-
UQ secures funds for development of skin cancer prevention cream
A research team at Australia's University of Queensland (UQ) has secured a A$344,000 grant from the National Foundation for Medical …
-
PrEP therapies offer new hope in HIV preventive landscape as vaccine failures amass
Research activity in the human immunodeficiency viruses space (HIV) is pivoting towards pre-exposure prophylaxis (PrEP) therapies as vaccine failures rack …
